Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Dragonfly Therapeutics
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Massachusetts General Hospital
University of Pittsburgh
University of California, San Francisco
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Coherus Oncology, Inc.
Bristol-Myers Squibb
Dragonfly Therapeutics
BioXcel Therapeutics Inc
University of Washington
Tempest Therapeutics
Incyte Corporation
Merck Sharp & Dohme LLC
MacroGenics
Xencor, Inc.
Incyte Corporation
Incyte Corporation
Trishula Therapeutics, Inc.
Merck Sharp & Dohme LLC
Trishula Therapeutics, Inc.
Merck Sharp & Dohme LLC
Thomas Jefferson University
Aprea Therapeutics
Hoosier Cancer Research Network
University of Colorado, Denver
UNICANCER
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
RAPT Therapeutics, Inc.
University of Michigan Rogel Cancer Center
University of Utah
University of California, San Francisco
Eli Lilly and Company
CG Oncology, Inc.
Tianjin Medical University Second Hospital
Southern Illinois University
Eli Lilly and Company
University Hospital, Ghent
Northwestern University
M.D. Anderson Cancer Center
Eli Lilly and Company
Advaxis, Inc.
Celldex Therapeutics
University of California, San Francisco